Cell Therapy in ACL Surgery May Provide Quicker Recovery in BPTB Transplantation
SAN DIEGO–(BUSINESS WIRE)– Cytori Therapeutics, Inc. (NASDAQ: CYTX) today reported positive results from a clinical study of Cytori Cell Therapy™ in anterior cruciate ligament (ACL) reconstruction of patients with ACL tears. The 6 month results from the first 20 patients with combination Cytori Cell Therapy and bone-patellar tendon-bone (BPTB) grafts were presented at the Barcelona Knee Symposium on November 20, 2014.
Dr. Ramon Cugat, co-director of the Orthopedic Institute, Hospital Quiron Barcelona and the lead investigator of the study, performed autologous bone-patellar tendon-bone (BPTB) transplantation to replace damaged ACLs in 20 athletes who had sustained injury. Cytori Cell Therapy utilizing adipose derived regenerative cells (ADRCs™) prepared by the Celution® System from a patient’s own fat was used with the BPTB graft during the transplantation procedure. The cell preparation, injection into the graft and transplantation of the graft were all performed in the same surgical procedure.
“We are extremely encouraged by these results. I have treated thousands of patients with ACL repair and think that Cytori Cell Therapy may have additional benefits over current standard of care. We believe that use of ADRCs processed with Cytori’s Celution System may translate into a more rapid recovery from a potentially career ending sports injury. We are hopeful that this could possibly lead to better quality grafts and improved graft strength,” said Dr. Cugat.
Dr. Cugat discussed the preliminary six month outcomes at the meeting. The procedure was feasible and not associated with safety issues above that seen with a standard small volume liposuction. All patients recovered without any complications. The results were compared to a historical control group of patients who had the same surgical procedure by the same surgical team but without other interventions. Overall, recovery from pain and ability to return to the field appeared to be accelerated as a result of the ADRC enriched BPTB transplant The patient questionnaires and serial magnetic resonance imaging (MRI) scans of the knees following cell therapy were consistent with accelerated healing of the graft.
Dr. Cugat and his team are obtaining one year follow-up information on the treated patients and intend to report and publish these results in the future.
About Cytori Therapeutics, Inc.
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat a variety of medical conditions. Multiple scientific publications suggest that Cytori Cell Therapy and ADRCs improve blood flow, moderate the inflammatory response and facilitate wound repair. As a result, we believe these cells can be applied with success across multiple disease states. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® System product family. For more information: visit www.cytori.com or follow on Twitter www.twitter.com/cytori
Cautionary Statement Regarding Forward-Looking Statements
This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our belief in the safety and feasibility in using Cytori Cell Therapy for treatment of BPTB transplantation related anterior cruciate ligament (ACL) tears and therapeutic potential to accelerate healing and recovery from pain with Cytori Cell Therapy for the treatment of such ligament injuries are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical, pre-clinical and regulatory uncertainties, particularly those inherent in the process of discovering, developing and commercializing therapies that are safe and effective for use as human therapeutics, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.
Source: Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.
Tiago Girao, 1-858-458-0900
Chief Financial Officer